Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Cash & Current Investments: 2016-2024

Historic Cash & Current Investments for Tg Therapeutics (TGTX) over the last 9 years, with Dec 2024 value amounting to $311.0 million.

  • Tg Therapeutics' Cash & Current Investments fell 30.86% to $235.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 38.88%. This contributed to the annual value of $311.0 million for FY2024, which is 42.98% up from last year.
  • Tg Therapeutics' Cash & Current Investments amounted to $311.0 million in FY2024, which was up 42.98% from $217.5 million recorded in FY2023.
  • Tg Therapeutics' Cash & Current Investments' 5-year high stood at $605.4 million during FY2020, with a 5-year trough of $161.7 million in FY2022.
  • Its 3-year average for Cash & Current Investments is $230.1 million, with a median of $217.5 million in 2023.
  • Per our database at Business Quant, Tg Therapeutics' Cash & Current Investments spiked by 331.11% in 2020 and then tumbled by 48.64% in 2022.
  • Yearly analysis of 5 years shows Tg Therapeutics' Cash & Current Investments stood at $605.4 million in 2020, then plummeted by 48.01% to $314.8 million in 2021, then tumbled by 48.64% to $161.7 million in 2022, then soared by 34.53% to $217.5 million in 2023, then soared by 42.98% to $311.0 million in 2024.